The adjuvant study ALTTO did not meet the primary endpoint of improved DFS with the addition of lapatinib to trastuzumab compared with trastuzumab as adjuvant treatment for HER2-positive early breast cancer [40]. This evidence concerns the gene ERBB2 and breast carcinoma.